| Literature DB >> 27626663 |
Sandra Hellberg1, Daniel Eklund2, Danuta R Gawel3, Mattias Köpsén4, Huan Zhang3, Colm E Nestor3, Ingrid Kockum5, Tomas Olsson5, Thomas Skogh6, Alf Kastbom6, Christopher Sjöwall6, Magnus Vrethem7, Irene Håkansson7, Mikael Benson3, Maria C Jenmalm1, Mika Gustafsson8, Jan Ernerudh9.
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS and has a varying disease course as well as variable response to treatment. Biomarkers may therefore aid personalized treatment. We tested whether in vitro activation of MS patient-derived CD4+ T cells could reveal potential biomarkers. The dynamic gene expression response to activation was dysregulated in patient-derived CD4+ T cells. By integrating our findings with genome-wide association studies, we constructed a highly connected MS gene module, disclosing cell activation and chemotaxis as central components. Changes in several module genes were associated with differences in protein levels, which were measurable in cerebrospinal fluid and were used to classify patients from control individuals. In addition, these measurements could predict disease activity after 2 years and distinguish low and high responders to treatment in two additional, independent cohorts. While further validation is needed in larger cohorts prior to clinical implementation, we have uncovered a set of potentially promising biomarkers.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27626663 DOI: 10.1016/j.celrep.2016.08.036
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423